Login Register Cart 0
Generic placeholder image

Current Stem Cell Research & Therapy

Editor-in-Chief

ISSN (Print): 1574-888X
ISSN (Online): 2212-3946

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Efficacy and Safety of Mesenchymal Stem Cell Therapy in Patients with Acute Myocardial Infarction: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Author(s): Jiang Yu, Run-feng Zhang*, Yi-li Mao and Heng Zhang

Volume 17, Issue 8, 2022

Published on: 16 August, 2021

Page: [793 - 807] Pages: 15

DOI: 10.2174/1574888X16666210816111031

Price: $65

Abstract

Background and Objectives: The adjuvant treatment of stem cell therapy for acute myocardial infarction (AMI) has been studied in multiple clinical trials, but many questions remain to be addressed, such as efficacy, safety, identification of the optimal cell type, tractable route of delivery, transplant dosage, and transplant timing.

The current meta-analysis aimed to explore the issues of mesenchymal stem cells (MSCs) transplantation in patients with AMI based on published randomized controlled trials (RCTs) and guide the design of subsequent clinical trials of MSCs therapy for AMI.

Methods: The Cochrane Library, PubMed, EMBASE databases were searched for relevant clinical trials from January 1, 2000, to January 23, 2021. Results from RCTs involving MSCs transplantation for the treatment of AMI were identified. According to the Cochrane systematic review method, the literature quality, including studies, was evaluated and valid data was extracted. Rev- Man 5.3 and Stata 15.1 software were used for Meta-analysis.

Results: After literature search and detailed evaluation, 9 randomized controlled trials enrolling 460 patients were included in the quantitative analysis. Pooled analyses indicated that MSCs therapy was associated with a significantly greater improvement in overall left ventricular ejection fraction (LVEF), and the effect was maintained for up to 24 months. No significant difference in favor of MSCs treatment in left ventricular (LV) volume and in the risk of rehospitalization as a result of heart failure (HF) was noted, compared with the controls. For transplantation dose, the LVEF of patients accepting a MSCs dose of 107-108 cells was significantly increased by 2.62% (95% CI 1.54 to 3.70; P < 0.00001; I2 =0%), but this increase was insignificant in the subgroup that accepted a MSCs dose of < 107 cells (1.65% in LVEF, 95% CI, 0.03 to 3.27; P =0.05; I2 =75%) or >108 cells (4.65% in LVEF, 95% CI, -4.55 to 13.48; P =0.32; I2 =95%), compared with the controls. For transplantation timing, a significant improvement of LVEF of 3.18% was achieved in the group of patients accepting a MSCs infusion within 2 to 14 days after percutaneous coronary intervention (PCI) (95% CI, 2.89 to 3.47; P <0.00001; I2 = 0). There was no association between MSCs therapy and major adverse events.

Conclusion: Results from our systematic review suggest that MSCs therapy for patients with AMI appears to be safe and might induce a significant increase in LVEF with a limited impact on LV volume and rehospitalization caused by HF. The effect was maintained for up to 24 months. MSCs dose of 107-108 cells was more likely to achieve better clinical endpoints than <107 or >108 cells. The optimal time window for cell transplantation might be within 2-14 days after PCI. This meta-analysis was registered with PROSPERO, number CRD 42021241104.

Keywords: Acute myocardial infarction (AMI), cell therapy, mesenchymal stem cells (MSCs), transplantation timing, cell doses, meta-analysis.

« Previous Next »
[1]
Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: A report from the american heart association. Circulation 2017; 135(10): e146-603.
[http://dx.doi.org/10.1161/CIR.0000000000000485] [PMID: 28122885]
[2]
Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction. Lancet 2017; 389(10065): 197-210.
[http://dx.doi.org/10.1016/S0140-6736(16)30677-8] [PMID: 27502078]
[3]
Hu XJ, Dong NG, Liu JP, Li F, Sun YF, Wang Y. Status on heart transplantation in China. Chin Med J 2015; 128(23): 3238-42.
[http://dx.doi.org/10.4103/0366-6999.170238] [PMID: 26612301]
[4]
Eschenhagen T, Bolli R, Braun T, et al. Cardiomyocyte regeneration: A consensus statement. Circulation 2017; 136(7): 680-6.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.117.029343] [PMID: 28684531]
[5]
Shi Y, Inoue H, Wu JC, Yamanaka S. Induced pluripotent stem cell technology: A decade of progress. Nat Rev Drug Discov 2017; 16(2): 115-30.
[http://dx.doi.org/10.1038/nrd.2016.245] [PMID: 27980341]
[6]
Terashvili M, Bosnjak ZJ. Stem cell therapies in cardiovascular disease. J Cardiothorac Vasc Anesth 2019; 33(1): 209-22.
[http://dx.doi.org/10.1053/j.jvca.2018.04.048] [PMID: 30029992]
[7]
Colombo A, Castellani M, Piccaluga E, et al. Myocardial blood flow and infarct size after CD133+ cell injection in large myocardial infarction with good recanalization and poor reperfusion: Results from a randomized controlled trial. J Cardiovasc Med 2011; 12(4): 239-48.
[http://dx.doi.org/10.2459/JCM.0b013e328343d708] [PMID: 21372740]
[8]
Quyyumi AA, Vasquez A, Kereiakes DJ, et al. PreSERVE-AMI: A randomized, double-blind, placebo-controlled clinical trial of intracoronary administration of autologous CD34+ cells in patients with left ventricular dysfunction post STEMI. Circ Res 2017; 120(2): 324-31.
[http://dx.doi.org/10.1161/CIRCRESAHA.115.308165] [PMID: 27821724]
[9]
Houtgraaf JH, den Dekker WK, van Dalen BM, et al. First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2012; 59(5): 539-40.
[http://dx.doi.org/10.1016/j.jacc.2011.09.065] [PMID: 22281257]
[10]
Gao LR, Chen Y, Zhang NK, et al. Intracoronary infusion of Wharton’s jelly-derived mesenchymal stem cells in acute myocardial infarction: Double-blind, randomized controlled trial. BMC Med 2015; 13(1): 162.
[http://dx.doi.org/10.1186/s12916-015-0399-z] [PMID: 26162993]
[11]
Fisher SA, Zhang H, Doree C, Mathur A, Martin-Rendon E. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev 2015; (9): CD006536.
[http://dx.doi.org/10.1002/14651858.CD006536.pub4] [PMID: 26419913]
[12]
Tao B, Cui M, Wang C, et al. Percutaneous intramyocardial delivery of mesenchymal stem cells induces superior improvement in regional left ventricular function compared with bone marrow mononuclear cells in porcine myocardial infarcted heart. Theranostics 2015; 5(2): 196-205.
[http://dx.doi.org/10.7150/thno.7976] [PMID: 25553108]
[13]
van der Spoel TI, Jansen of Lorkeers SJ, Agostoni P, et al. Human relevance of pre-clinical studies in stem cell therapy: Systematic review and meta-analysis of large animal models of ischaemic heart disease. Cardiovasc Res 2011; 91(4): 649-58.
[http://dx.doi.org/10.1093/cvr/cvr113] [PMID: 21498423]
[14]
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med 2021; 18(3): e1003583.
[http://dx.doi.org/10.1371/journal.pmed.1003583] [PMID: 33780438]
[15]
Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: A new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 2019; 10: ED000142.
[http://dx.doi.org/10.1002/14651858.ED000142] [PMID: 31643080]
[16]
Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
[http://dx.doi.org/10.1136/bmj.d5928] [PMID: 22008217]
[17]
Barde MP, Barde PJ. What to use to express the variability of data: Standard deviation or standard error of mean? Perspect Clin Res 2012; 3(3): 113-6.
[http://dx.doi.org/10.4103/2229-3485.100662] [PMID: 23125963]
[18]
Wang X, Xi WC, Wang F. The beneficial effects of intracoronary autologous bone marrow stem cell transfer as an adjunct to percutaneous coronary intervention in patients with acute myocardial infarction. Biotechnol Lett 2014; 36(11): 2163-8.
[http://dx.doi.org/10.1007/s10529-014-1589-z] [PMID: 24975729]
[19]
Chen SL, Fang WW, Ye F, et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004; 94(1): 92-5.
[http://dx.doi.org/10.1016/j.amjcard.2004.03.034] [PMID: 15219514]
[20]
Gao LR, Pei XT, Ding QA, et al. A critical challenge: Dosage-related efficacy and acute complication intracoronary injection of autologous bone marrow mesenchymal stem cells in acute myocardial infarction. Int J Cardiol 2013; 168(4): 3191-9.
[http://dx.doi.org/10.1016/j.ijcard.2013.04.112] [PMID: 23651816]
[21]
Lee JW, Lee SH, Youn YJ, et al. A randomized, open-label, multicenter trial for the safety and efficacy of adult mesenchymal stem cells after acute myocardial infarction. J Korean Med Sci 2014; 29(1): 23-31.
[http://dx.doi.org/10.3346/jkms.2014.29.1.23] [PMID: 24431901]
[22]
Kim SH, Cho JH, Lee YH, et al. Improvement in left ventricular function with intracoronary mesenchymal stem cell therapy in a patient with anterior wall ST-segment elevation myocardial infarction. Cardiovasc Drugs Ther 2018; 32(4): 329-38.
[23]
Zhang RF, Yu J, Zhang NK, et al. Bone marrow mesenchymal stem cells transfer in patients with ST-segment elevation myocardial infarction:single blind,multicenter,randomized controlled trial. Stem Cell Res Ther 2021; 12(1): 33-47.
[http://dx.doi.org/10.1186/s13287-020-02096-6] [PMID: 33413636]
[24]
Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009; 54(24): 2277-86.
[http://dx.doi.org/10.1016/j.jacc.2009.06.055] [PMID: 19958962]
[25]
Chullikana A, Majumdar AS, Gottipamula S, et al. Randomized, double-blind, phase I/II study of intravenous allogeneic mesenchymal stromal cells in acute myocardial infarction. Cytotherapy 2015; 17(3): 250-61.
[http://dx.doi.org/10.1016/j.jcyt.2014.10.009] [PMID: 25484310]
[26]
Shafei AE, Ali MA, Ghanem HG, et al. Mesenchymal stem cell therapy: A promising cell-based therapy for treatment of myocardial infarction. J Gene Med 2017; 19(12): e2995.
[http://dx.doi.org/10.1002/jgm.2995] [PMID: 29044850]
[27]
Heldman AW, DiFede DL, Fishman JE, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA 2014; 311(1): 62-73.
[http://dx.doi.org/10.1001/jama.2013.282909] [PMID: 24247587]
[28]
Bagno L, Hatzistergos KE, Balkan W, Hare JM. Mesenchymal stem cell-based therapy for cardiovascular disease: Progress and challenges. Mol Ther 2018; 26(7): 1610-23.
[http://dx.doi.org/10.1016/j.ymthe.2018.05.009] [PMID: 29807782]
[29]
Perin EC, Borow KM, Silva GV, et al. A phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic or nonischemic heart failure. Circ Res 2015; 117(6): 576-84.
[http://dx.doi.org/10.1161/CIRCRESAHA.115.306332] [PMID: 26148930]
[30]
Florea V, Rieger AC, DiFede DL, et al. Dose comparison study of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy (The TRIDENT Study). Circ Res 2017; 121(11): 1279-90.
[http://dx.doi.org/10.1161/CIRCRESAHA.117.311827] [PMID: 28923793]
[31]
Khodayari S, Khodayari H, Amiri AZ, et al. Inflammatory microenvironment of acute myocardial infarction prevents regeneration of heart with stem cells therapy. Cell Physiol Biochem 2019; 53(5): 887-909.
[http://dx.doi.org/10.33594/000000180] [PMID: 31749350]
[32]
Xu JY, Qian HY, Huang PS, et al. Transplantation efficacy of autologous bone marrow mesenchymal stem cells combined with atorvastatin for acute myocardial infarction (TEAM-AMI): Rationale and design of a randomized, double-blind, placebo-controlled, multi-center, Phase II TEAM-AMI trial. Regen Med 2019; 14(12): 1077-87.
[http://dx.doi.org/10.2217/rme-2019-0024] [PMID: 31829095]
[33]
Sun L, Zhang T, Lan X, Du G. Effects of stem cell therapy on left ventricular remodeling after acute myocardial infarction: a meta-analysis. Clin Cardiol 2010; 33(5): 296-302.
[PMID: 20513068]
[34]
de Jong R, Houtgraaf JH, Samiei S, Boersma E, Duckers HJ. Intracoronary stem cell infusion after acute myocardial infarction: a meta-analysis and update on clinical trials. Circ Cardiovasc Interv 2014; 7(2): 156-67.
[http://dx.doi.org/10.1161/CIRCINTERVENTIONS.113.001009] [PMID: 24668227]
[35]
Wang Y, Xu F, Ma J, et al. Effect of stem cell transplantation on patients with ischemic heart failure: A systematic review and meta-analysis of randomized controlled trials. Stem Cell Res Ther 2019; 10(1): 125.
[http://dx.doi.org/10.1186/s13287-019-1214-0] [PMID: 30999928]
[36]
Fan M, Huang Y, Chen Z, et al. Efficacy of mesenchymal stem cell therapy in systolic heart failure: A systematic review and meta-analysis. Stem Cell Res Ther 2019; 10(1): 150.
[http://dx.doi.org/10.1186/s13287-019-1258-1] [PMID: 31151406]
[37]
Fu H, Chen Q. Mesenchymal stem cell therapy for heart failure: A meta-analysis. Herz 2020; 45(6): 557-63.
[http://dx.doi.org/10.1007/s00059-018-4762-7] [PMID: 30341444]
[38]
Shen T, Xia L, Dong W, et al. A systematic review and meta-analysis: Safety and efficacy of mesenchymal stem cells therapy for heart failure. Curr Stem Cell Res Ther 2021; 16(3): 354-65.
[PMID: 32867655]
[39]
Wang Z, Wang L, Su X, Pu J, Jiang M, He B. Rational transplant timing and dose of mesenchymal stromal cells in patients with acute myocardial infarction: A meta-analysis of randomized controlled trials. Stem Cell Res Ther 2017; 8(1): 21.
[http://dx.doi.org/10.1186/s13287-016-0450-9] [PMID: 28129790]
[40]
Jeyaraman MM, Rabbani R, Copstein L, et al. Autologous bone marrow stem cell therapy in patients with ST-elevation myocardial infarction: A systematic review and meta-analysis. Can J Cardiol 2017; 33(12): 1611-23.
[http://dx.doi.org/10.1016/j.cjca.2017.10.001] [PMID: 29173601]
[41]
Omar AM, Meleis AE, Arfa SA, Zahran NM, Mehanna RA. Comparative study of the therapeutic potential of mesenchymal stem cells derived from adipose tissue and bone marrow on acute myocardial infarction model. Oman Med J 2019; 34(6): 534-43.
[http://dx.doi.org/10.5001/omj.2019.97] [PMID: 31745418]
[42]
Hass R, Kasper C, Böhm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal 2011; 9: 12.
[http://dx.doi.org/10.1186/1478-811X-9-12] [PMID: 21569606]
[43]
Donders R, Bogie JFJ, Ravanidis S, et al. Human Wharton’s jelly-derived stem cells display a distinct immunomodulatory and proregenerative transcriptional signature compared to bone marrow-derived stem cells. Stem Cells Dev 2018; 27(2): 65-84.
[http://dx.doi.org/10.1089/scd.2017.0029] [PMID: 29267140]
[44]
Chien KR, Frisén J, Fritsche-Danielson R, Melton DA, Murry CE, Weissman IL. Regenerating the field of cardiovascular cell therapy. Nat Biotechnol 2019; 37(3): 232-7.
[http://dx.doi.org/10.1038/s41587-019-0042-1] [PMID: 30778231]
[45]
Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002; 105(1): 93-8.
[http://dx.doi.org/10.1161/hc0102.101442] [PMID: 11772882]
[46]
Hatzistergos KE, Quevedo H, Oskouei BN, et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res 2010; 107(7): 913-22.
[http://dx.doi.org/10.1161/CIRCRESAHA.110.222703] [PMID: 20671238]
[47]
Sid-Otmane C, Perrault LP, Ly HQ. Mesenchymal stem cell mediates cardiac repair through autocrine, paracrine and endocrine axes. J Transl Med 2020; 18(1): 336.
[http://dx.doi.org/10.1186/s12967-020-02504-8] [PMID: 32873307]
[48]
Chen J, Liu Z, Hong MM, et al. Proangiogenic compositions of microvesicles derived from human umbilical cord mesenchymal stem cells. PLoS One 2014; 9(12): e115316.
[http://dx.doi.org/10.1371/journal.pone.0115316] [PMID: 25514634]
[49]
Zhang Z, Yang J, Yan W, Li Y, Shen Z, Asahara T. Pretreatment of cardiac stem cells with exosomes derived from mesenchymal stem cells enhances myocardial repair. J Am Heart Assoc 2016; 5(1): e002856.
[http://dx.doi.org/10.1161/JAHA.115.002856] [PMID: 26811168]
[50]
Jackson MV, Morrison TJ, Doherty DF, et al. Mitochondrial transfer via tunneling nanotubes is an important mechanism by which mesenchymal stem cells enhance macrophage phagocytosis in the in vitro and in vivo models of ARDS. Stem Cells 2016; 34(8): 2210-23.
[http://dx.doi.org/10.1002/stem.2372] [PMID: 27059413]

Rights & Permissions Print Cite
Article Metrics
20
2
© 2024 Bentham Science Publishers | Privacy Policy